Select Conferences

Cellumen to Collaborate with the NCTR of the FDA to Apply Cellular Systems Biology to Predictive Toxicology
Cellumen will use its proprietary CellCiphr® toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds.

pSivida Announces Interim Results from the Three-Month Readout of the Human PK Medidur™ FA Study
The three-month human pharmacokinetic study is designed to support the ongoing pivotal Phase III clinical trial of Medidur in DME.

Compugen Announces Discovery of Biomarkers for Early Pre-Clinical Detection of Drug-Induced Kidney Toxicity
Data demonstrate that the biomarker signature may enable a much earlier prediction of drug-induced kidney toxicity during pre-clinical trials.

ValiRx Announces Promising In Vivo Results for its Lead Molecule VAL 101
VAL 101 uses company’s gene silencing technology GeneICE™ in preclinical xenograph models of pancreatic cancer.

DOCKING STUDIES OF A NEW HETEROCYCLIC METHYLTHIOMORPHOLIN PHENOLS DERIVATIVES AS ANTIHYPERTENSIVE DRUGS WITH ACE TARGET.CASE FESCDIPINE II
1) Departamento de C. Químicas FESC, UNAM, 2) Facultad de C. Química UNACH, 3) Facultad de Química, UAEM, 4) Facultad de Medicina UNAM

As part of the Drug Design in Medicinal Chemistry Program of the UNAM, new methylthiomorpholinphenol compounds with cardiovascular effect, were studied. One of them, FESCDIPINE II, was an excellent antihypertensive drug, that has low toxicity and preliminary studies indicate that the Angiotensin-converting enzyme (ACE) system is the biological target of this compound.

A Novel Design of Artificial Membrane for Improving the PAMPA Model
BD Biosciences - Discovery Labware

The Parallel Artificial Membrane Permeability Assay (PAMPA) is a well-accepted screening assay for ADME properties (membrane permeability).

Validation of Time-Dependent Cytochrome P450 Inhibition assays: Use of Stable - Labeled Isotope Internal Standards for Optimal Quantitation
BD Biosciences – Discovery Labware

Time-dependent inhibition of cytochrome P450 (CYP) metabolism can lead to nonlinear pharmacokinetics and drug-drug interactions. Recent guidance from the USFDA and drug failures attributable to toxicity that may have a basis in time-dependent inhibition, have elevated interest in this long-known undesirable property of drug candidates.

Regulatory Services Business Development
Recruiter: VRS Regulatory
Central Scotland, UK

Team Leader, Bioanalysis
Biodynamics Research Limited
Rushden, Northants, UK

Regulatory Toxicologist
VRS Regulatory
Cheshire, UK

Metabonomics Scientist
Nestlé Research Center
Lausanne, Switzerland

NanoBio Commercialisation Manager
Cenamps
Newcastle Upon Tyne, UK

Laboratory Technician
Peptide Protein Research
UK

Direct Sales - LCMS Product Specialist
Agilent Technologies
Multiple US Regions

Account Manager
Evolution Life Science
West Midlands, UK

Project Manager
Evolution Life Science
South East, UK

Sales Specialist
Evolution Life Science
Cambridge/East Midlands, UK

Bioanalytical Scientist
Evolution Life Science
North West, UK

Pre/Post Inside Sales Applications Manager - Analytical Instruments and Supplies
Agilent Technologies
Wilmington, DE, USA

Peptide Purification Lab
New England Peptide, Inc.
Gardner, MA, USA

Ion Channel Targets, South San Francisco, California, USA
09 October 2008 - 10 October 2008

Select Biosciences is proud to announce their 4th annual Ion Channel Targets conference and exhibition. This year's event will take place at the South San Francisco Conference Center. Alongside an exhibition of selected scientific posters and service providers, Select Biosciences is organizing a two day event gathering some of the most influential players in the field from America and across the globe. The full two day agenda includes sessions on Calcium Channels, Potassium Channels, Sodium Chan
  


In silico ADMET Traffic Lights and PhysChem Scores and Their Application to Kinase Inhibitors

Mario Lobell, Computational Chemist, Bayer HealthCare, speaking at Virtual Discovery, 2007


Virtual Screening in Lead Discovery

Hugo Kubinyi, Professor of Pharmaceutical Chemistry, University of Heidelberg, speaking at Virtual discovery 2007

High-Content Analysis 2007
Published April 2007

This report presents an industry analysis of the High-Content Analysis Marketplace in both qualitative and quantitative terms. High-Content Analysis involves the use of instrumentation, reagents, and informatics to perform multi-parametric analysis of biological systems—ie., lots of different cellular parameters studied in parallel.

Ion Channel Trends 2006
Published July 2006

This market report summarizes the results of the third annual global Pharma/Biotech and Academic web-based benchmarking survey on ion channels. The objectives of this study were to better understand the impact of automated patch clamping (APC) and to gauge if its use will widen over the coming years, and to determine current interest and future requirements for ion channel screening using primary neural cells.

A High Throughput Approach for Metabolite Profiling and Characterization Using the LXQ Linear Ion Trap Mass Spectrometer
Thermo Fisher Scientific

A high throughput LC-MS/MS approach has been developed for metabolic profiling using the LXQ linear ion trap mass spectrometer. The rapid LC-MS/MS method made use of Data-Dependent™ acquisitions to study known metabolites and to uncover unexpected metabolites. The identification and characterization of glyburide along with 19 metabolites was accomplished in a single LC run of approximately three minutes using the fast cycle time, high sensitivity and excellent spectral quality of this instrument